Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease

J Cutan Med Surg. 2018 Sep/Oct;22(5):507-510. doi: 10.1177/1203475418758986. Epub 2018 Feb 27.

Abstract

The incidence of anti-tumour necrosis factor (TNF)-induced psoriasiform eruptions has ranged in the literature between 0.5% and 10.9% of patients with inflammatory bowel disease (IBD). The morphology of the rash varies, with plaque psoriasis being the most common form. Generalized pustular eruption is reported in 10.2% of cases of anti-TNF-induced psoriasis. We are reporting a unique case of anti-TNF-associated psoriasiform eruption due to the severity of the rash presenting as a generalized pustular eruption in association with plaque psoriasiform rash requiring systemic therapy.

Keywords: TNF complication; TNF-induced psoriasis; paradoxical psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Gastrointestinal Agents / adverse effects*
  • Gastrointestinal Agents / therapeutic use
  • Hand / pathology
  • Humans
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab / adverse effects*
  • Infliximab / therapeutic use
  • Leg / pathology
  • Psoriasis* / chemically induced
  • Psoriasis* / complications
  • Psoriasis* / diagnosis
  • Psoriasis* / pathology
  • Skin / pathology
  • Young Adult

Substances

  • Gastrointestinal Agents
  • Infliximab